Literature DB >> 18367485

Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma.

Judith Dierlamm1, Eva M Murga Penas, Stefan Bentink, Swen Wessendorf, Hilmar Berger, Michael Hummel, Wolfram Klapper, Dido Lenze, Andreas Rosenwald, Eugenia Haralambieva, German Ott, Sergio B Cogliatti, Peter Möller, Carsten Schwaenen, Harald Stein, Markus Löffler, Rainer Spang, Lorenz Trümper, Reiner Siebert.   

Abstract

BACKGROUND: The aim of this study was to determine the impact of a gain of the MALT1 gene on gene expression and clinical parameters in diffuse large B-cell lymphoma. DESIGN AND METHODS: We analyzed 116 cases of diffuse large B-cell lymphoma by fluorescence in situ hybridization, array-based comparative genomic hybridization, and transcriptional profiling.
RESULTS: A gain of 18q21 including MALT1 was detected in 44 cases (38%) and was accompanied by a gain of BCL2 in 43 cases. All cases with a 18q21/MALT1 gain showed BCL2 protein whereas 79% in the group without a 18q21/MALT1 gain did so (p<0.001). Cases with 18q21/MALT1 gain more frequently showed an activated B-cell-like (ABC) gene expression signature (65%) than a germinal center B-cell-like (GCB) one (23%) (p<0.001). Ninety-eight genes including MALT1, BCL2, and some selected nuclear factor-kappaB target genes were differentially expressed between the two genetic groups of diffuse large B-cell lymphoma. By global testing of each chromosome, we identified 33 genes, all located on chromosome 18q, which were differentially expressed between the two genetic groups independently of the ABC/GCB status. In multivariate analysis, the 18q21/MALT1 status represented an independent negative prognostic factor for overall survival (p=0.03).
CONCLUSIONS: In diffuse large B-cell lymphoma, gain of 18q21 including MALT1 is significantly associated with differential expression of genes located on 18q, the ABC gene expression subtype, increased BCL2 gene and protein expression and might indicate an unfavorable prognosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18367485     DOI: 10.3324/haematol.12057

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  18 in total

1.  Cross-platform assessment of genomic imbalance confirms the clinical relevance of genomic complexity and reveals loci with potential pathogenic roles in diffuse large B-cell lymphoma.

Authors:  Lizalynn M Dias; Venkata Thodima; Julia Friedman; Charles Ma; Asha Guttapalli; Geetu Mendiratta; Imran N Siddiqi; Sergei Syrbu; R S K Chaganti; Jane Houldsworth
Journal:  Leuk Lymphoma       Date:  2015-11-16

2.  MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.

Authors:  Lorena Fontan; Chenghua Yang; Venkataraman Kabaleeswaran; Laurent Volpon; Michael J Osborne; Elena Beltran; Monica Garcia; Leandro Cerchietti; Rita Shaknovich; Shao Ning Yang; Fang Fang; Randy D Gascoyne; Jose Angel Martinez-Climent; J Fraser Glickman; Katherine Borden; Hao Wu; Ari Melnick
Journal:  Cancer Cell       Date:  2012-12-11       Impact factor: 31.743

Review 3.  Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.

Authors:  Regan Stephenson; Ankur Singh
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

4.  Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth.

Authors:  Lorena Fontán; Qi Qiao; John M Hatcher; Gabriella Casalena; Ilkay Us; Matt Teater; Matt Durant; Guangyan Du; Min Xia; Natalia Bilchuk; Spandan Chennamadhavuni; Giuseppe Palladino; Giorgio Inghirami; Ulrike Philippar; Hao Wu; David A Scott; Nathanael S Gray; Ari Melnick
Journal:  J Clin Invest       Date:  2018-07-19       Impact factor: 14.808

5.  BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma.

Authors:  Samantha L Kendrick; Lucas Redd; Andrea Muranyi; Leigh A Henricksen; Stacey Stanislaw; Lynette M Smith; Anamarija M Perry; Kai Fu; Dennis D Weisenburger; Andreas Rosenwald; German Ott; Randy D Gascoyne; Elaine S Jaffe; Elías Campo; Jan Delabie; Rita M Braziel; James R Cook; Raymond R Tubbs; Louis M Staudt; Wing Chung Chan; Christian Steidl; Thomas M Grogan; Lisa M Rimsza
Journal:  Hum Pathol       Date:  2014-06-26       Impact factor: 3.466

6.  Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile.

Authors:  M Chin; M Herscovitch; N Zhang; D J Waxman; T D Gilmore
Journal:  Oncogene       Date:  2009-04-20       Impact factor: 9.867

7.  Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.

Authors:  Tomoko Takimoto-Shimomura; Taku Tsukamoto; Saori Maegawa; Yuto Fujibayashi; Yayoi Matsumura-Kimoto; Yoshimi Mizuno; Yoshiaki Chinen; Yuji Shimura; Shinsuke Mizutani; Shigeo Horiike; Masafumi Taniwaki; Tsutomu Kobayashi; Junya Kuroda
Journal:  Invest New Drugs       Date:  2018-06-21       Impact factor: 3.850

8.  The potential of copy number gains and losses, detected by array-based comparative genomic hybridization, for computational differential diagnosis of B-cell lymphomas and genetic regions involved in lymphomagenesis.

Authors:  Ichiro Takeuchi; Hiroyuki Tagawa; Akira Tsujikawa; Masao Nakagawa; Miyuki Katayama-Suguro; Ying Guo; Masao Seto
Journal:  Haematologica       Date:  2008-11-23       Impact factor: 9.941

9.  B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.

Authors:  Gero Knittel; Paul Liedgens; Darya Korovkina; Jens M Seeger; Yussor Al-Baldawi; Mona Al-Maarri; Christian Fritz; Katerina Vlantis; Svetlana Bezhanova; Andreas H Scheel; Olaf-Oliver Wolz; Maurice Reimann; Peter Möller; Cristina López; Matthias Schlesner; Philipp Lohneis; Alexander N R Weber; Lorenz Trümper; Louis M Staudt; Monika Ortmann; Manolis Pasparakis; Reiner Siebert; Clemens A Schmitt; Andreas R Klatt; F Thomas Wunderlich; Stephan C Schäfer; Thorsten Persigehl; Manuel Montesinos-Rongen; Margarete Odenthal; Reinhard Büttner; Lukas P Frenzel; Hamid Kashkar; H Christian Reinhardt
Journal:  Blood       Date:  2016-04-05       Impact factor: 22.113

10.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

Authors:  Bjoern Chapuy; Chip Stewart; Andrew J Dunford; Jaegil Kim; Atanas Kamburov; Robert A Redd; Mike S Lawrence; Margaretha G M Roemer; Amy J Li; Marita Ziepert; Annette M Staiger; Jeremiah A Wala; Matthew D Ducar; Ignaty Leshchiner; Ester Rheinbay; Amaro Taylor-Weiner; Caroline A Coughlin; Julian M Hess; Chandra S Pedamallu; Dimitri Livitz; Daniel Rosebrock; Mara Rosenberg; Adam A Tracy; Heike Horn; Paul van Hummelen; Andrew L Feldman; Brian K Link; Anne J Novak; James R Cerhan; Thomas M Habermann; Reiner Siebert; Andreas Rosenwald; Aaron R Thorner; Matthew L Meyerson; Todd R Golub; Rameen Beroukhim; Gerald G Wulf; German Ott; Scott J Rodig; Stefano Monti; Donna S Neuberg; Markus Loeffler; Michael Pfreundschuh; Lorenz Trümper; Gad Getz; Margaret A Shipp
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.